Current Report Filing (8-k)
April 01 2021 - 5:26PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported): April 1, 2021 (March 31, 2021)
Inspyr
Therapeutics, Inc.
(Exact
name of registrant as specified in Charter)
Delaware
|
|
0001421204
|
|
20-0438951
|
(State
or other jurisdiction of
incorporation or organization)
|
|
(Commission
File No.)
|
|
(IRS
Employee
Identification No.)
|
2629
Townsgate Road, Suite 215
Westlake
Village CA 91361
(Address
of Principal Executive Offices)
818-661-6302
(Issuer
Telephone number)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
Registered pursuant to Section 12(b) of the Act:
Title
of Class
|
|
Trading
Symbol
|
|
Name
of Each Exchange on Which Registered
|
N/A
|
|
N/A
|
|
N/A
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth
company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On
March 31, 2021, Inspyr Therapeutics, Inc. (the “Company”) reported its financial results for the year ended December
31, 2020. A copy of the press release is attached as Exhibit 99.01 and is incorporated herein by reference.
The
information furnished under Items 2.02, including the accompanying Exhibit 99.01 shall not be deemed to be “filed”
for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to
the liability of such section, nor shall such information be deemed to be incorporated by reference in any subsequent filing by
the Company under the Securities Act of 1933 or the Exchange Act, regardless of the general incorporation language of such filing,
except as specifically stated in such filing.
Item 9.01 Financial Statements and Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed
on its behalf by the undersigned hereunto duly authorized.
Dated:
April 1, 2021
|
Inspyr Therapeutics, Inc.
|
|
|
|
|
By:
|
/s/
Michael Cain
|
|
|
Michael
Cain
Chief
Executive Officer
|
INDEX
OF EXHIBITS